Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Epilepsy

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

50% or greater reduction in seizure frequency · patients with AD and epileptic seizures

It is very uncertain whether levetiracetam changes reduction in seizure frequency of 50% or more compared with phenobarbital (very low certainty).

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
RR 1.11 [0.78, 1.56]
1 study · 66 participants
Very low

Proportion with seizure freedom in dominantly inherited AD · patients with AD and epileptic seizures

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in cognition · patients with AD and epileptic seizures

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

Change in neuropsychiatric symptoms · patients with AD and epileptic seizures

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

Improvement in quality of life · patients with AD and epileptic seizures

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Seizure freedom · patients with AD and epileptic seizures

It is very uncertain whether levetiracetam changes proportion with seizure freedom compared with phenobarbital (very low certainty).

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
RR 1.01 [0.47, 2.19]
1 study · 66 participants
Very low

Proportion with adverse events · patients with AD and epileptic seizures

It is very uncertain whether levetiracetam changes proportion with adverse events compared with phenobarbital (very low certainty).

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
RR 0.44 [0.18, 1.07]
1 study · 66 participants
Very low